This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clarke, K. Articles by Veech, R. L. Search for Related Content PubMed PubMed Citation Articles by Clarke, K. Articles by Veech, R. L.

(Circulation. 1995;91:2299-2301.)
© 1995 American Heart Association, Inc.

Articles

Metabolic Complexities in Cardiac Imaging

Kieran Clarke, PhD; Richard L. Veech, MD, DPhil

From the Department of Biochemistry (K.C.), University of Oxford, Oxford, UK; and LMMB (R.L.V.), NIAAA, Rockville, Md.

Correspondence to Dr Richard L. Veech, LMMB, NIAAA, 12501 Washington Ave, Rockville, MD 20852.

Key Words: imaging • editorials • metabolism

	Introduction

 
For patients with advanced ischemic heart disease, positron emission tomography (PET) is a reimbursable method for identifying those suitable for revascularization. This will probably increase the use of PET in deciding whether potentially life-enhancing, but costly, interventions will be performed. In this issue of Circulation, an important article by Taegtmeyer and colleagues¹ shows that it may not be possible to use the seductive, computer-derived colored images produced by PET as a quantitative measure of myocardial metabolic rate. These researchers have shown that accumulation of [2-¹⁸F]fluoro-2-deoxy-D-glucose (FDG), a widely used PET tracer, does not give an accurate measure of glucose metabolism under many of the physiological, metabolic, and hormonal conditions experienced by the heart.

Modeling of FDG as a glucose analogue for glycolysis in the heart comes in large part from work in brain metabolism,² where glucose is the major metabolic fuel and glycogen synthesis from glucose is essentially nil. In contrast, the heart is omnivorous in its choice of metabolic fuels, with a preference for fatty acids and with considerable glycogen synthesis and degradation.^{3 4} Consequently, expressions such as "myocardial glucose metabolism" and "myocardial glucose utilization" were coined in part out of recognition that FDG flux rates are unable to distinguish glycogen synthesis from glycolysis. In the heart, therefore, a measure of the rate of FDG accumulation may be just that—a measure of FDG accumulation and not a measure of metabolic rate.

If one is to interpret the meaning of a change in FDG accumulation over time, . . . [Full Text of this Article]

This article has been cited by other articles:

				M. V. Simoes, S. Egert, S. Ziegler, M. Miyagawa, S. Reder, T. Lehner, N. Nguyen, M. J. Charron, and M. Schwaiger Delayed response of insulin-stimulated fluorine-18 deoxyglucose uptake in glucose transporter-4-null mice hearts J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1690 - 1697. [Abstract] [Full Text] [PDF]

				S. Egert, N. Nguyen, F. C Brosius III, and M. Schwaiger Effects of wortmannin on insulin- and ischemia-induced stimulation of GLUT4 translocation and FDG uptake in perfused rat hearts Cardiovasc Res, August 1, 1997; 35(2): 283 - 293. [Abstract] [Full Text] [PDF]